Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective

  title={Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective},
  author={Crystal Jing Jing Yeo and Zachary Simmons},
  journal={Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration},
  pages={167 - 172}
  • C. YeoZ. Simmons
  • Published 15 January 2018
  • Medicine
  • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare… 

Integration of a palliative care specialist in an amyotrophic lateral sclerosis clinic: Observations from one center

Patients with complex goals of care may benefit from the input of a palliative care specialist, and unique integration models may help to facilitate care delivery.

Palliative care in motor neurone disease: where are we now?

  • D. Oliver
  • Medicine, Psychology
    Palliative care
  • 2019
The aim of palliative care is to enable patients, and their families, to maintain as good a quality of life as possible and helping to ensure a peaceful death.

Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies

The main downsides to the UK approach are that cost‐effective medications are often available months later than in the US, and some medications remain unavailable, whereas they are available at cost‐ effective prices in the UK.

Gamisoyo-San Ameliorates Neuroinflammation in the Spinal Cord of hSOD1G93A Transgenic Mice

GSS inhibits the expression of proteins related to Toll-like receptor 4 signaling and oxidative stress, known to cause neuroinflammation, and regulates metabolism in the spinal cord of transgenic mice, suggesting that GSS could be used for improving the immune system and increasing the life quality of patients with ALS.

Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners

The diagnostic delay of ALS appears to be proportionately very long, sometimes longer than that observed in previous studies (because it also included the total delay to diagnostic or treatment initiation); the rapid execution of useful additional tests by the first medical doctor, often GP (with the help of a neurologist), considerably reduces the diagnostic delay.

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

Evidence in support of the disease-modifying effects of EH301 for the treatment of ALS is provided, shown to significantly slow the progression of ALS relative to placebo, and even showed improvements in several key outcome measures compared with baseline.

Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis

Pooled evidence shows that perampanel compared to placebo significantly improves cortical motor hyperexcitability but not the ALS functional rating scale-revised score, and there is no sufficient evidence to support the role of perampsanel in improving functional status of ALS patients.

NIV in amyotrophic lateral sclerosis: The ‘when’ and ‘how’ of the matter

Non‐invasive ventilation in ALS has been considerably improved as a result of application of all of these measures, avoiding the need for tracheostomy in the very great majority of cases.

Psychosoziale Versorgung bei Patienten mit Amyotropher Lateralsklerose: Ein narrativer Review

Dieser narrative Review soll einen breiten Überblick zur psychosozialen Belastung bei Patienten mit Amyotropher Lateralsklerose (ALS) und diesbezüglichen psychotherapeutischen Interventionen

Amiyotrofik Lateral Skleroz Tedavisinde Güncel Onaylanmış Hastalık Modifiye Edici Tedavi: Riluzol ve Edaravone

Motor noron hastaliginin prototipi olan Amiyotrofik lateral Skleroz (ALS) patogenezinin tam olarak anlasilamamis olmasi ve hastaligin yuz guldurucu bir tedavisinin olmamasi tani surecini hasta ve



July 2017 ENCALS statement on edaravone

It was showed that edaravone may slow disease progression in ALS, but the disease-modifying effect was limited to a subgroup of ALS patients with distinct clinical characteristics, and for ALS patients without those characteristics there is currently no evidence for a therapeutic benefit of edarvone.

Is quality of life determined by expectations or experience?

It is argued that perceptions of health and its meaning vary between individuals and within an individual over time and a model of the relation between expectations and experience is proposed to illustrate problems in measuring quality of life.

Health literacy : a prescription to end confusion

Health Literacy: Prescription to End Confusion examines the body of knowledge that applies to the field of health literacy, and recommends actions to promote a health literate society.

Correlates of suffering in amyotrophic lateral sclerosis

Many patients with ALS suffer and their suffering is correlated to pain and hopelessness, and the correlates of poor quality of life were poor social support and increasing hopelessness.

Quality of life in fatal disease: the flawed judgement of the social environment

It is suggested that caregivers and the general public significantly underestimate the quality of life (QoL) of ALS patients and a positive affective state can indeed be preserved in a progressive, fatal disease.

Quality of life in ALS is maintained as physical function declines

QOL in patients with ALS appears to be independent of physical function, which agrees with a previous cross-sectional study, and the ALS-specific health-related QOL score is primarily a measure ofPhysical function.

Disparities in perceptions of distress and burden in ALS patients and family caregivers

Caregivers can accurately report information about a patient’s physical function at the end of life, however, patients and caregivers each overestimated the psychosocial impact of the disease on the other.

Assessing decision-making capacity at end of life.

Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations

The PPK analyses demonstrated no clinically relevant difference in the PK profiles of edaravone by race, sex, weight, or age, according to a virtual population based on ALS clinical trials.